PRIMARY OBJECTIVES:
I. Evaluate the association between pre-treatment diversity of the fecal microbiome and major pathological response to neoadjuvant chemotherapy in operable pancreatic ductal adenocarcinoma patients.
II. Evaluate the association between pre-treatment HEI-2015 dietary score and major pathological response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients.
III. Evaluate the association between pre-treatment HEI-2015 dietary score and diversity of the fecal microbiome in pancreatic ductal adenocarcinoma patients.
OUTLINE: This is an observational study.
Patients complete a dietary survey and undergo fecal sample collection on study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\* Age ≥ 18 years with signed informed consent form
* Patients must have a histological diagnosis of PDAC
* Resectable or borderline resectable PDAC on imaging
You may not be if
\* Patients with locally advanced and metastatic stage IV PDAC
* Patients who have already received or completed neoadjuvant chemotherapy for PDAC
* Patients with active malignancy receiving systemic therapy
